Reviewed by Michael Gill, B. Sc.
11 Marginal Zone Lymphoma Clinical Trials Near Me
Top Hospitals for Marginal Zone Lymphoma Clinical Trials
Image of Sharp Memorial Hospital in California.
Sharp Memorial Hospital
San Diego
2Active Trials
2All Time Trials for Marginal Zone Lymphoma
2019First Marginal Zone Lymphoma Trial
Image of Asclepes Research Centers in Florida.
Asclepes Research Centers
Weeki Wachee
2Active Trials
2All Time Trials for Marginal Zone Lymphoma
2017First Marginal Zone Lymphoma Trial
Top Cities for Marginal Zone Lymphoma Clinical Trials
Image of New York in New York.
New York
5Active Trials
Nyu Clinical Cancer CenterTop Active Site
Image of Houston in Texas.
Houston
4Active Trials
Md Anderson Cancer CenterTop Active Site
Marginal Zone Lymphoma Clinical Trials by Phase of Trial
Phase 1 Marginal Zone Lymphoma Clinical Trials
1Active Marginal Zone Lymphoma Clinical Trials
1Number of Unique Treatments
8Number of Active Locations
Marginal Zone Lymphoma Clinical Trials by Age Group
Most Recent Marginal Zone Lymphoma Clinical Trials
Top Treatments for Marginal Zone Lymphoma Clinical Trials
Treatment Name
Active Marginal Zone Lymphoma Clinical Trials
All Time Trials for Marginal Zone Lymphoma
First Recorded Marginal Zone Lymphoma Trial
Loncastuximab tesirine 150 µg/Kg
1
1
2022
Zanubrutinib
1
5
2016
Mosunetuzumab
1
2
2022
tafasitamab
1
1
2021
Venetoclax
1
7
2018
Recently Completed Studies with FDA Approved Treatments for Marginal Zone Lymphoma
Treatment
Year
Sponsor
Zanubrutinib
2019
BeiGene
PI3K inhibitor BKM120
2014
Kami Maddocks, MD

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: November 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Phillips T, Jurczak W, Ribrag V, Linton K, Collin GP, Lopéz-Jimenéz J, Reddy N, Mengarelli A, Musuraca G, Sheehy O, Xu W, Azoulay M, Ghalie RG, Zinzani PL, Zelenetz AD. IBCL-271 Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S387-S388. doi: 10.1016/S2152-2650(22)01555-5. https://pubmed.ncbi.nlm.nih.gov/36164104